New Grants Fund Novel Approaches to Cancer Research

GENEROUS PLEDGES to create new funding opportunities will enable Lurie Cancer Center investigators to develop innovative and potentially life-saving research across disciplines.

IDP Foundation Funds Research Innovation Challenge Grants

The IDP Foundation, Inc., of Chicago recently pledged $1 million to create the IDP Foundation Research Innovation Challenge Grants at the Lurie Cancer Center. These "idea" or "seed" grants will provide Lurie Cancer Center scientists and clinicians with crucial resources to ask novel research questions and explore new ideas relating to cancer.

» Read more...

Lefkofsky Family Foundation Supports Innovative Studies in Cancer

The Lefkofsky Family Foundation of Chicago recently pledged to create the Liz and Eric Lefkofsky Innovation Research Awards at the Lurie Cancer Center. These awards will help to support promising Lurie Cancer Center investigators as they develop a research track record that will lead to National Institutes of Health (NIH) funding for their basic, translational, and clinical cancer studies, raising the bar for scientific discovery by rewarding ingenuity.

» Read more...

Deadline to apply for the initial Liz and Eric Lefkofsky Innovation Awards is October 1, 2014. View proposal guidelines.

Zafirovski Named Interim Associate Director of Administration

ALEKSANDER ZAFIROVSKI, MBA, has been named Interim Associate Director of Administration for the Lurie Cancer Center. Zafirovski will continue to serve as the Director of Oncology Operations at Northwestern Memorial Hospital, where he has been instrumental in driving the efforts that led to the successful launch and continuing expansion of the Northwestern Medicine Developmental Therapeutics Institute (NMDTI).

A recognized leader in oncology administration, Zafirovski is active in local, regional and national professional societies, and has given numerous related lectures. “Alex is superbly positioned to help lead our ongoing initiatives to integrate and optimize the Lurie Cancer Center’s vital cancer-related activities,” said Leonidas Platanias, MD, PhD, Interim Director of the Lurie Cancer Center.
New Signaling Pathway in Brain Tumors Identified

Scientists have identified a new signaling pathway by investigating the role of a protein, DCBLD2, in glioblastomas, a deadly type of brain tumor and head and neck cancers.

The role of DCBLD2 in human cancers is not fully understood or studied in human cancers including glioblastomas. Shi-Yuan Cheng, PhD, Professor of Neurology at Feinberg, and his team found high levels of these proteins in glioblastoma tumor specimens and examined how they function in cancer cell lines in glioblastomas and head and neck cancers.

Cheng’s results describe how this pathway leads to enhanced tumor growth. Cheng found that DCBLD2 works along with receptor protein EGFR that is a so-called “cancer driver” to activate other proteins that drive tumor growth, development and resistance to treatments.

“We showed that expression of DCBLD2 is increased in clinical glioblastomas and demonstrated that DCBLD2 signals a chain reaction causing EGFR to drive tumor growth,” said Cheng, a member of the Lurie Cancer Center and part of Northwestern Brain Tumor Institute. Furthermore, his study revealed a close correlation between expression of these proteins along with poor prognoses in patients with glioblastomas and head and neck cancers.

“The role of DCBLD2 in cancer progression and tumorigenesis suggests the necessity and feasibility of targeting this protein in the tumor and in developing effective treatments for human cancers,” Cheng said.

» Read more...

New Skin Gel Fights Breast Cancer Without Blood Risk

A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects that deter some women from taking it, according to new research led by Seema Khan, MD, Professor of Surgery and the Bluhm Family Professor of Cancer Research at the Feinberg School of Medicine.

The gel was tested on women diagnosed with the non-invasive cancer ductal carcinoma in situ (DCIS) in which abnormal cells multiply and form a growth in a milk duct. Because of potential side effects, many women with DCIS are reluctant to take oral tamoxifen after being treated with breast-saving surgery and radiation even though the drug effectively prevents DCIS recurrence and reduces risk of future new breast cancer.

“Delivering the drug though a gel, if proven effective in larger trials, could potentially replace oral tamoxifen for breast cancer prevention and DCIS and encourage many more women to take it,” said Khan, co-leader of the Women’s Cancer Research Program at the Lurie Cancer Center. “For breast cancer prevention and DCIS therapy, effective drug concentrations are required in the breast. For these women, high circulating drug levels only cause collateral damage.”

“The gel minimized exposure to the rest of the body and concentrated the drug in the breast where it is needed,” Khan said. “There was very little drug in the bloodstream which should avoid potential blood clots as well as an elevated risk for uterine cancer.”

» Read more...
Study Helps Explain Chronic Inflammation in Colon Cancer

A MULTI-DISCIPLINARY team of scientists from Northwestern Medicine and the University of Chicago investigated how lymphocytes, a type of white blood cell, increase inflammation in the body during colon cancer. It is well known that varying numbers and types of lymphocytes infiltrate colon tumors, yet the role they play in cancer progression is not fully understood.

"More than half of the cells in solid tumors aren't cancer cells, so we wanted to understand what these cells are doing and if they influence outcomes in colon cancer patients," said Lurie Cancer Center member, David Bentrem, MD, Harold L. and Margaret N. Method Research Professor of Surgery at Feinberg. "We took tumors out of patients, isolated the lymphocytes, and were able to find subsets of regulatory T-cells that promoted inflammation. Next, the team focused on how these cells became pro-inflammatory."

Their findings confirmed the role the protein plays in promoting the disease and shows how it contributes to intestinal inflammation and colon carcinogenesis in those with underlying colitis. These results allow physicians to not only understand how inflammation in colon cancer occurs, but also provide insight into ways to create more effective treatment plans for patients.

» Read more...

Biomarker in an Aggressive Breast Cancer is Identified

NORTHEASTERN UNIVERSITY scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, a protein called STAT3, provides a smart target for new therapeutics designed to treat this often deadly cancer.

Using breast cancer patient data taken from The Cancer Genome Atlas, Lurie Cancer Center member Curt M. Horvath, PhD, and Robert Tell, PhD, used powerful computational and bioinformatics techniques to detect patterns of gene expression in two cancer subtypes. They found that a small number of genes are activated by STAT3 protein signaling in basal-like breast cancers but not in luminal breast cancers.

Basal-like cancer is a category that includes a number of different breast cancers, including the highly aggressive form called triple negative cancer. "You can’t treat breast cancer as one disease," said Horvath, a Professor of Molecular Biosciences in the Weinberg College of Arts and Sciences, and a Professor of Microbiology-Immunology and of Medicine at the Feinberg School of Medicine. "Cancer describes many molecular processes that have gone wrong. We have teased out from large amounts of data that STAT3 activity correlates with distinct patterns of gene expression in one type of breast cancer but not in another."

Previous research has found the STAT3 protein to be overactive in many breast cancers, but its role has not been well understood. Horvath and Tell’s research is the first reported study to compare breast cancer subtypes and gene expression patterns associated with STAT3 in the tumors of human patients.

» Read more...

New Instrument Tracks Nanoparticles in Cancer Cells

GAYLE WOLOSCHAK, PhD, Professor of Radiation Oncology and Radiology at Feinberg, created nanoparticles to target and destroy cancer cells, but when she wanted to see where they traveled within cells, traditional x-ray imaging did not work. "My main goal is delivering nanoparticles to the nucleus of a cancer cell where they can do the most damage," she said. "When the nanoparticles are activated by radiation, it’s almost like dropping a bomb in a cancer cell, they explode."

Traditional x-ray imaging penetrates through cells, making it difficult to determine whether nanoparticles are above, below or inside the nucleus. Most other microscopy methods destroy the cell in the process of taking the image.

Woloschak and a team of scientists from the Argonne National Laboratory, Northwestern Synchrotron Research Center and Carl Zeiss X-ray Microscopy developed Bionanoprobe, the first and only x-ray fluorescent microscopy instrument that allows researchers to take three-dimensional images of nanoparticles in cells. "The idea was to create something different than anything else in the world," said Woloschak, a member of the Lurie Cancer Center. "We developed a tool that has 3D images, uses frozen cells – which is the closest you can get to live cells – and can detect any element on the periodic table. The resolution is so sensitive that it can even quantitate how many atoms of a metal are in the sample."

» Read more...
YOUNG ADULT CANCER survivors reported poorer physical and emotional health but better social health compared to their peers in a study by Lurie Cancer Center scientists. The study focused on the five year period following the end of cancer treatment for young adults aged 18 to 39 years old.

“Early adulthood is challenging enough. A cancer diagnosis can make it exponentially more difficult because normal developmental transitions – education, moving, new jobs, dating, having kids – are sometimes put on hold,” said Primary Investigator John Salsman, PhD, Research Assistant Professor of Medical Social Sciences at Feinberg.

Other concerns may outweigh those traditional transitions, concerns about the possible loss of fertility, prematurely confronting mortality, body image, managing symptoms from treatment and the disease, and fear of recurrence. The scientists compared the cancer survivors to a healthy cohort, matching age, education, sex and partner status.

“This allows us to put our findings in the appropriate context and begin to tease apart the differences in quality of life due to normal developmental challenges versus those due to the cancer experience,” said Salsman. “With this better understanding, supportive oncology providers can anticipate future challenges and allocate resources to provide care and minimize the negative impact of cancer.”

> Read more...

THE SUMMER OF 2014 marked the 16th year that the Lurie Cancer Center’s CURE (Continuing Umbrella of Research Experience) Program enabled undergraduate students to experience firsthand what it is like to work in a cancer research laboratory. Ten students were selected—from an applicant pool of over 150 majoring in the biological sciences—to spend eight weeks conducting cancer research in the laboratory under the guidance of a Lurie Cancer Center faculty mentor.

In addition to their lab training, the students met every Friday to hear a seminar on various topics in cancer research and receive career counseling. At the end of the program, each student gave an oral PowerPoint presentation of their results to faculty and participating lab members. “It is very rewarding to watch the students’ growth over the course of the summer. At first, the students are scared and very hesitant, but at the final presentations they are confident and enthusiastic. In fact, several students have expressed an interest in continuing the research at their own institutions or at Northwestern during winter break or next year,” said Robin Leikin, PhD, CURE Program Director and a Research Assistant Professor at the Lurie Cancer Center.

The CURE students will continue their undergraduate education at Brown University, Northwestern University, Spelman College, Hampton University, Harvard University, Boston University, University of Wisconsin, Johns Hopkins University and the University of Houston. The CURE Program is supported by a supplement grant from the National Cancer Institute. 160 students have participated since Leikin first organized the program at Northwestern in 1999.
Erik Andersen, PhD, Assistant Professor of Molecular Biosciences in the Weinberg College of Arts and Sciences, has been named a 2014 Pew Scholar in the Biomedical Sciences. Pew Scholars are selected for demonstrated excellence and innovation in research relevant to the advancement of human health. One of 22 Pew Scholars named this year nationwide, Andersen’s research explores how multiple genes interacting with each other and with the environment can control biomedical and agricultural traits.

Mary J.C. Hendrix, PhD, President and Scientific Director, Stanley Manne Children’s Research Institute, was honored by the American Committee for the Weizmann Institute of Science with its 2014 Vision & Impact Award. This award recognizes individuals whose commitment and dedication have made a major difference in their communities. The American Committee shares a common vision with the Weizmann Institute of Science in Israel in advancing science for the benefit of humanity.

Melina Kibbe, MD, the Edward G. Elcock Professor of Surgical Research and Vice Chair of Research in the Department of Surgery at the Feinberg School of Medicine, has been named Editor-in-Chief of the scientific journal, JAMA Surgery, effective January 1, 2015. Kibbe is the Edward G. Elcock Professor of Surgical Research and Vice Chair of Research in the Department of Surgery at the Feinberg School of Medicine.

Chad Mirkin, PhD, Director of Northwestern’s International Institute for Nanotechnology, received the 2014 ACS Nano Lectureship Award. Three scientists from around the globe whose work has significantly impacted the fields of nanoscience and nanotechnology were honored in 2014, with one awardee each from the Americas, Europe/Middle East/Africa, and Asia/Pacific. The award was presented in July at NANO 2014 in Moscow.

Richard I. Morimoto, PhD, the Bill and Gayle Cook Professor of Molecular Biosciences in the Weinberg College of Arts and Sciences, was awarded the 2014 Feodor Lynen Medal from the German Biochemical Society. The award recognizes outstanding contributions to the biological sciences. Morimoto is recognized for his research on the regulation of the heat shock stress response and the function of molecular chaperones.

Simone Sredni, MD, PhD, Research Assistant Professor of Neurological Surgery at the Feinberg School of Medicine, received a grant from the Rally Foundation for Childhood Cancer Research to support her investigations of malignant rhabdoid tumors (MRT), among the most aggressive and unresponsive tumors in pediatric oncology.

Kristin Swanson, PhD, Professor of Neurological Surgery at the Feinberg School of Medicine, received a James S. McDonnell Foundation Grant for her lab’s ENDURES (Environmental Dynamics Underlying Responsive Extreme Survivors of Glioblastoma) study of extreme long-term survivors of Glioblastoma Multiforma to characterize treatment responses and the causes of disease progression.
THE LURIE CANCER CENTER is committed to educating the public about cancer prevention and treatment, and offers a wide range of community events and patient programs throughout the year. Below is a list of programs scheduled through November 2014.

LEARN MORE AND REGISTER AT cancer.northwestern.edu or call 312.695.1390

---

**Illinois Blood Cancer Conference**

**Saturday, September 13, 2014**

Hamburger University, Oak Brook

Jane Winter, MD, will discuss “Clinical Trial Participation: The Real Story” at this free program providing information about treatment and side effect management for patients and families.

---

**Metastatic Meet Up**

**Sunday, October 19, 2014**

Lurie Medical Research Center

Offered before the Lynn Sage Breast Cancer Town Hall for patients living with metastatic breast cancer, this free program is hosted in partnership with the Metastatic Breast Cancer Network.

---

**Lynn Sage Breast Cancer Town Hall**

**Sunday, October 19, 2014**

Lurie Medical Research Center

A free interactive discussion about breakthrough in breast cancer research is an opportunity for patients and families to ask questions about new therapies and treatment options, family history, nutrition and rehabilitation after cancer. Exhibits highlight breast cancer resources, and local and national organizations providing support.

---

**Brain Tumor Patient and Caregiver Forum**

**Monday, October 20, 2014**

Lurie Medical Research Center

Brain tumor patients and caregivers will learn about clinical trials, the role of palliative care, and innovative approaches to research at Northwestern Brain Tumor Institute.

---

**Rock Out Women's Cancer: "No Evidence of Disease" Movie Screening**

**Tuesday, October 21, 2014**

Lurie Medical Research Center

Music and medicine join forces in this award-winning documentary about six gynecologic cancer surgeons who form a rock band. A discussion with oncologist and N.E.D. drummer Nimesh Nagarsheth, MD, and Lurie Cancer Center oncologist, Emily Berry, MD, will follow the free screening.

---

**Cancer Connections**

**Saturday, November 8, 2014**

Northwestern Memorial Hospital, Feinberg Pavilion

Offered quarterly, this series of public education programs introduces patients, caregivers and health care professionals to tools and strategies for improving health and quality of life before, during and after cancer treatment.
Fundraising Events

Septembeard
Think you’ll look better with a beard? Join Septembeard in supporting prostate cancer research at the Lurie Cancer Center.

Lou Malnati’s Cancer Research Benefit
Saturday, September 13, 2014
Meadows Club, Rolling Meadows
The 44th Annual evening of fun benefits Northwestern Brain Tumor Institute.

Rooftop Cocktail Party
Tuesday, September 23, 2014
Ivy Hotel SKY Terrace, Chicago
Benefits Northwestern Brain Tumor Institute’s Patient and Family Assistance Fund.

Get Your Rear in Gear 5K Run/Walk
Saturday, September 27, 2014
Montrose Harbor, Chicago
Help the Colon Cancer Coalition and the Chris4Life Colon Cancer Foundation support colon cancer screening in Chicago and research at the Lurie Cancer Center.

Lung Force Walk
Sunday, September 28, 2014
Hamburger University, Oak Brook
In partnership with Northwestern Medicine, the American Lung Association in Greater Chicago is supporting lung cancer research, advocacy and education through LUNG FORCE

In Good Taste: A Breast Cancer Research Initiative
Wine and dine for a good cause in October! The Lynn Sage Foundation is partnering with more than 150 Chicagoland establishments to raise funds; enabling the Lurie Cancer Center to recruit talented leaders in breast cancer research through the Lynn Sage Scholars Program at Northwestern University.

Lynn Sage Cancer Research Foundation Fall Benefit Luncheon
Tuesday, October 14, 2014
Hilton Chicago
Actress, director and producer, Sally Field, will be the special guest speaker at the Lynn Sage Cancer Research Foundation’s annual fundraiser. Proceeds will support breast cancer research, education programs and fellowships at Northwestern Medicine and the Lurie Cancer Center.

Head for the Cure
Sunday, October 26, 2014
Diversey Harbor, Chicago
Funds raised support the Brain Tumor Trials Collaborative, a network of institutions with expertise and commitment to clinical trials. The Chicago 5K will also benefit Northwestern Brain Tumor Institute.
THROUGHOUT THE YEAR, the Lurie Cancer Center offers professional education on various cancer related topics. Below is a list of programs scheduled through November 2014.

**LEARN MORE AND REGISTER AT**
cancer.northwestern.edu or call 312.695.1391

---

**Bone Marrow Failure Disease 2014 Symposium**

**Chair:** Brady Stein, MD  
Northwestern University, Feinberg School of Medicine  
**September 18, 2014**  
Prentice Women's Hospital, Conference Room L

**2014 Oncofertility Conference**

**Chair:** Teresa Woodruff, PhD  
Northwestern University, Feinberg School of Medicine  
**September 22-23, 2014**  
Prentice Women's Hospital, Conference Room L

**16th Annual Lynn Sage Breast Cancer Symposium**

**Chair:** William Gradishar, MD  
Northwestern University, Feinberg School of Medicine  
**Co-Chair:** Monica Morrow, MD  
Memorial Sloan-Kettering Cancer Center  
**Co-Chair:** V. Craig Jordan, OBE, PhD, DSc  
Georgetown University, Lombardi Comprehensive Cancer Center  
**October 9 - 12, 2014**  
The Fairmont Chicago  
lynnsgabreastcancer.org

---

**Chung Lee Seminar**

**Impact of Inflammation on Prostate Stem Cells**

**Speaker:** Timothy Ratliff, PhD  
Purdue University Center for Cancer Research  
**October 9, 2014**  
Robert H. Lurie Medical Research Center, Searle Seminar Room

**Nathanial Berlin Lectureship**

**Status of CART T-Cells for Therapy of Cancer**

**Speaker:** Carl H. June, MD  
University of Pennsylvania, Abramson Cancer Center  
**October 21, 2014**  
Robert H. Lurie Medical Research Center, Hughes Auditorium

**Oncology Nursing Conference**

**Survivorship: From Diagnosis & Beyond**

**Keynote Speaker:** Nancy Jo Bush, MN, RN, MA, AOCN  
UCLA School of Nursing  
**November 21-22, 2014**  
Feinberg Pavilion, Conference Rooms A-D

---

**Weekly Lectures**

**GRAND ROUNDS**

Wednesdays: 12:00 p.m. to 1:00 p.m  
Sponsored by the Division of Hematology/Oncology, Feinberg School of Medicine and the Lurie Cancer Center. This activity has been approved for 1 **AMA PRA Category 1 Credit™**  
» Schedule at cancer.northwestern.edu/grandrounds

**TUMOR CELL BIOLOGY**

Thursdays: 1:00 p.m. to 2:00 p.m.  
» Schedule at cancer.northwestern.edu/tcb

To receive weekly reminders about Grand Rounds or TCB Seminars please contact Denise Marshall at d-marshall4@northwestern.edu.
Travel Grants

Travel Fellowship Awards

The Katten Muchin Rosenman Travel Scholarship Program allows doctoral students and postdoctoral fellows to present the results of their basic cancer research.

The Center for Genetic Medicine Travel Fellowship allows doctoral students and postdoctoral fellows to present the results of their basic cancer research showing its genetics relevance.

The Cancer Prevention Travel Scholarship Program allows doctoral students and postdoctoral fellows to present the results of their laboratory, clinical, population or behavioral research with implications for cancer prevention.

The next deadline to apply for 2014 Travel Fellowship Awards is November 7, 2014.

» Details and application here

Liz and Eric Lefkofsky Innovation Research Awards

The Lurie Cancer Center is soliciting proposals from both beginning and senior investigators for new, highly innovative, cancer-relevant pilot studies that can serve as foundations for larger, nationally funded studies. Proposals for basic, translational, or clinical pilot studies will be considered. All applicants must be tenured or tenure-track faculty members.

Two proposals will be funded at $75,000 for a term of one year in 2014. One of the funded studies will be eligible for a second year of funding at $100,000. Funding may be available to support additional highly meritorious and novel proposals.

The application deadline for the initial awards is October 1, 2014.

» Details and application here

Basic Sciences Research Division

H Foundation Incentive Awards provide funding for faculty who have submitted and received a score on a RO1 grant to the NCI for the first time in their career. If additional funds are available, awards will be made to other faculty for new, first-time NCI RO1 submissions, which are scored but not yet funded.

H Foundation Bridge Awards provide up to $20,000 of support for competing renewals of NCI-sponsored RO1 research that missed the payline.

Applications for H Foundation Incentive and Bridge Awards are reviewed on a rolling basis and accepted until funds for the year are expended.

» Details and application here

Lea Charitable Trust Equipment Grants

Through the generous support of the Lea Charitable Trust, a pool of funds is available to full members of the Lurie Cancer Center affiliated with one of the Basic Sciences Research Programs for use by multiple investigators or to support small equipment grants for collaborative research projects.

Lea Charitable Trust Equipment Grants are made on a rolling basis as funds become available.

» Details and application here

Big Ten Cancer Research Consortium Oncology Trial Concepts

The Big Ten Cancer Research Consortium (BTCRC) is actively seeking concepts for highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The BTCRC is setting the goal to receive at least one new concept from each institution during 2014.

Once submitted, concepts will be discussed through a clinical trial working group mechanism. These disease-specific working groups are another way to increase collaboration across the BTCRC institutions and provide an opportunity for senior investigators to mentor junior investigators throughout the development of these translational trials.

» Details & application here
Welcome New Members

Lurie Cancer Center Appoints New Members

**Young Kwang Chae, MD, MPH,** is an Assistant Professor of Hematology/Oncology at the Feinberg School of Medicine. A medical oncologist and clinical investigator, Chae is seeing patients with advanced cancer refractory to standard of care treatments. His primary research focus is on first-in-human clinical trials and associated biomarker development.

As a faculty member of the Northwestern Medicine Developmental Therapeutics Institute, Chae is involved in the development of novel pathway-driven clinical trials for many different types of solid tumors.

Contact Dr. Chae at young.chae@northwestern.edu or 312.472.1234

**Sunandana Chandra, MD, MS,** is an Assistant Professor of Medical Oncology at the Feinberg School of Medicine. Chandra, a medical oncologist and clinical investigator whose primary research focus is on melanoma, is working with the Northwestern Skin Cancer Institute to develop translational based clinical trials to treat cutaneous malignancies.

Chandra is also a faculty member of the Northwestern Medicine Developmental Therapeutics Institute, where she is involved in the development of novel clinical trials for many different types of cancers.

Contact Dr. Chandra at sunandana.chandra@northwestern.edu or 312.472.1234

**Rintaro Hashizume, MD, PhD,** is an Assistant Professor of Neurological Surgery at the Feinberg School of Medicine. His primary research interests are in understanding of the molecular mechanisms that affect the aggressive/infiltrative biological behavior of malignant glioma and would accordingly reveal potential therapeutic targets.

In addition, Hashizume is interested in utilizing the animal model system to enhance the testing of new therapeutic agents being considered for clinical trials, and as a tool for understanding genetic and biological abnormalities of malignant glioma.

Contact Dr. Chandra at rintaro.hashizume@northwestern.edu or 312-503-3822

**Derek Wainwright, PhD,** is an Assistant Professor of Neurological Surgery at the Feinberg School of Medicine. His research is focused on utilizing DNA sequencing, gene expression profiling, proteomic analyses, flow cytometric methodology, and many other basic techniques to pursue goals that are ultimately translatable for improving health and overall survival in patients with brain cancer.

Wainwright’s research is primarily focused on malignant glioma, with a special emphasis on glioblastoma, however, he is also interested in pursuing incurable pediatric brain tumors, as well as metastatic tumors that invade the brain/spinal cord.

Contact Dr. Wainwright at derekwainwright@northwestern.edu or 312.503.3161
Welcome New Staff

what’s new

Lurie Cancer Center
Office of Public Affairs and Communications
676 N. St. Clair
Suite 1200
Chicago, IL 60611
312.695.1304

Interim Director
Leonidas Platanias, MD, PhD

Director,
Public Affairs and Communications
Sharon Markman

Interim Associate Director, Administration
Aleksander Zafirovski, MBA

Managing Editor
Jennifer Bowker

Help Wanted:
Reporters

PLEASE SEND SUGGESTIONS for this newsletter to Jennifer Bowker, j-bowker@northwestern.edu

Lurie Cancer Center Weekly Updates

INFORMATION TO BE CONSIDERED for inclusion in the Lurie Cancer Center’s weekly e-mail updates must be received at least two weeks in advance. Submit suggestions to Denise Marshall at d-marshall4@northwestern.edu.

Sumail Bhogal
Data Assistant 2
Clinical Research Office
sumail.bhogal@northwestern.edu

Lauren Bontemps
Clinical Research Coordinator
Clinical Research Office
lauren.bontemps@northwestern.edu

Debansu Ghosh
Senior Research Administrator
Business Operations
debansu.ghosh@northwestern.edu

Laura Sharp
Data Assistant 2
Clinical Research Office
laura.sharp@northwestern.edu

Matthew Winter
Regulatory Coordinator
Clinical Research Office
m-winter@northwestern.edu

Zachary Kisley
Data Assistant 2
Clinical Research Office
zachary.kisley@northwestern.edu

Chiara Rodgers
Clinical Research Coordinator
Clinical Research Office
chiara.rogers@northwestern.edu

Chiara Rodgers
Clinical Research Coordinator
Clinical Research Office
chiara.rogers@northwestern.edu

Laura Sharp
Data Assistant 2
Clinical Research Office
laura.sharp@northwestern.edu

Matthew Winter
Regulatory Coordinator
Clinical Research Office
m-winter@northwestern.edu

Lurie Cancer Center
Office of Public Affairs and Communications
676 N. St. Clair
Suite 1200
Chicago, IL 60611
312.695.1304

Interim Director
Leonidas Platanias, MD, PhD

Director,
Public Affairs and Communications
Sharon Markman

Interim Associate Director, Administration
Aleksander Zafirovski, MBA

Managing Editor
Jennifer Bowker

Help Wanted:
Reporters

PLEASE SEND SUGGESTIONS for this newsletter to Jennifer Bowker, j-bowker@northwestern.edu

Lurie Cancer Center Weekly Updates

INFORMATION TO BE CONSIDERED for inclusion in the Lurie Cancer Center’s weekly e-mail updates must be received at least two weeks in advance. Submit suggestions to Denise Marshall at d-marshall4@northwestern.edu.